SITE013-0042

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-04-18

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-02 (study day 5); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-02 (study day 5); relationship: N

severe assessed

Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-05 (study day 8); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-14 (study day 17); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 18); relationship: N

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-26 (study day 29); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-31 (study day 34); relationship: not assessed

mild assessed

Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-06-02 (study day 36); relationship: not assessed

severe assessed

Grade 3 Hyperthyroidism — outcome: RECOVERED/RESOLVED; onset 2022-06-07 (study day 41); relationship: not assessed

Data queries

No data queries.